US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Articles published by Bolt Biotherapeutics, Inc.

News headline image
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Participate in Upcoming March Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Announces Changes to its Board of Directors
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Participate in Upcoming September Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics to Participate in September Investor Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
News headline image
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT